Scholarlink

<p>Loss-of-function genomic alterations in <i>FANCA</i> occur across multiple cancer types, yet no molecularly tailored therapies have successfully exploited this potential vulnerability. Using complementary unbiased approaches, including a genome-wide CRISPR/Cas9 loss-of-function screen and a high-throughput drug screen in isogenic cancer cell-based models, we identified Aurora kinase A (AURKA) as a reproducible synthetic lethal target of FANCA-deficient cancers. Inhibition of AURKA induced chromosomal instability, micronucleation, and differential mitotic dynamics dependent on FANCA status. Mechanistically, FANCA deficiency is associated with an elevated AURKA expression at both the transcriptomic and protein levels, and with an upregulation of mitotic spindle and G2/M checkpoint gene signatures. Analysis of large-scale cancer genomics datasets, including over 650,000 clinically sequenced tumors, confirms that <i>FANCA</i> is the most frequently altered Fanconi anemia pathway gene across cancers, and that Fanconi anemia–defective tumors exhibit an increased tumor mutational burden and genomic instability. Collectively, our findings point to AURKA inhibition as a promising precision treatment strategy in FANCA-deficient cancers and provide a rationale to further explore this strategy in the clinic.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Aurora kinase A is a synthetic lethal target in FANCA-deficient cancers

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月11日

查看全文
  • Dilara Akhoundova,
  • Martín González-Fernández,
  • Aavash Baral,
  • Andrej Benjak,
  • Carmen Perry,
  • Dinda Shezaria Hardy Lubis,
  • Ladina Hörtensteiner,
  • Saskia Hussung,
  • Lea Lingg,
  • Sina Maletti,
  • Aino Paasinen-Sohns,
  • Marika Lehner,
  • Bastian Dislich,
  • Erik Vassella,
  • Simone de Brot,
  • Therese Waldburger,
  • Petros Tsiridis,
  • Carmen Cardozo,
  • Ralph Fritsch,
  • Clelia Pistoni,
  • Seynabou Diop,
  • Phillip Thienger,
  • Taina Kaiponen,
  • Muriel Jaquet,
  • Mariana Ricca,
  • Smruthy Sivakumar,
  • Christopher McDermott-Roe,
  • David E. Root,
  • Paola Francica,
  • Sven Rottenberg,
  • Mark A. Rubin

摘要

Loss-of-function genomic alterations in FANCA occur across multiple cancer types, yet no molecularly tailored therapies have successfully exploited this potential vulnerability. Using complementary unbiased approaches, including a genome-wide CRISPR/Cas9 loss-of-function screen and a high-throughput drug screen in isogenic cancer cell-based models, we identified Aurora kinase A (AURKA) as a reproducible synthetic lethal target of FANCA-deficient cancers. Inhibition of AURKA induced chromosomal instability, micronucleation, and differential mitotic dynamics dependent on FANCA status. Mechanistically, FANCA deficiency is associated with an elevated AURKA expression at both the transcriptomic and protein levels, and with an upregulation of mitotic spindle and G2/M checkpoint gene signatures. Analysis of large-scale cancer genomics datasets, including over 650,000 clinically sequenced tumors, confirms that FANCA is the most frequently altered Fanconi anemia pathway gene across cancers, and that Fanconi anemia–defective tumors exhibit an increased tumor mutational burden and genomic instability. Collectively, our findings point to AURKA inhibition as a promising precision treatment strategy in FANCA-deficient cancers and provide a rationale to further explore this strategy in the clinic.